Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
The aims of this multicentric retrospective study were to assess in a real-world setting the effectiveness and safety of canagliflozin 100 mg/d (CANA100) as an add-on to the background antihyperglycemic therapy, and to evaluate the intensification of prior sodium–glucose co-transporter type 2 inhibi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/9/7/2275 |
| _version_ | 1797562195783974912 |
|---|---|
| author | Juan J. Gorgojo-Martínez Manuel A. Gargallo-Fernández Alba Galdón Sanz-Pastor Teresa Antón-Bravo Miguel Brito-Sanfiel Jaime Wong-Cruz |
| author_facet | Juan J. Gorgojo-Martínez Manuel A. Gargallo-Fernández Alba Galdón Sanz-Pastor Teresa Antón-Bravo Miguel Brito-Sanfiel Jaime Wong-Cruz |
| author_sort | Juan J. Gorgojo-Martínez |
| collection | DOAJ |
| description | The aims of this multicentric retrospective study were to assess in a real-world setting the effectiveness and safety of canagliflozin 100 mg/d (CANA100) as an add-on to the background antihyperglycemic therapy, and to evaluate the intensification of prior sodium–glucose co-transporter type 2 inhibitor (SGLT-2i) therapy by switching to canagliflozin 300 mg/d (CANA300) in patients with T2DM. One cohort of SGLT2i-naïve patients with T2DM who were initiated on CANA100 and a second cohort of patients with prior background SGLT-2i therapy who switched to CANA300 were included in the study. The primary outcome of the study was the mean change in HbA1c over the follow-up time. In total, 583 patients were included—279 in the cohort of CANA100 (HbA1c 8.05%, weight 94.9 kg) and 304 in the cohort of CANA300 (HbA1c 7.51%, weight 92.0 kg). Median follow-up periods in both cohorts were 9.1 and 15.4 months respectively. CANA100 was associated to significant reductions in HbA1c (−0.90%) and weight (−4.1 kg) at the end of the follow-up. In those patients with baseline HbA1c > 8% (mean 9.25%), CANA100 lowered HbA1c levels by 1.51%. In the second cohort, patients switching to CANA300 experienced a significant decrease in HbA1c (−0.35%) and weight (−2.1 kg). In those patients with baseline HbA1c > 8% (mean 8.94%), CANA300 lowered HbA1c levels by 1.12%. There were significant improvements in blood pressure in both cohorts. No unexpected adverse events were reported. In summary, CANA100 (as an add-on therapy) and CANA300 (switching from prior SGLT-2i therapy) significantly improved several cardiometabolic parameters in patients with T2DM. |
| first_indexed | 2024-03-10T18:24:51Z |
| format | Article |
| id | doaj.art-8ac015594a2b4ae9b6ff8c605b520b57 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T18:24:51Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-8ac015594a2b4ae9b6ff8c605b520b572023-11-20T07:04:31ZengMDPI AGJournal of Clinical Medicine2077-03832020-07-0197227510.3390/jcm9072275Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan StudyJuan J. Gorgojo-Martínez0Manuel A. Gargallo-Fernández1Alba Galdón Sanz-Pastor2Teresa Antón-Bravo3Miguel Brito-Sanfiel4Jaime Wong-Cruz5Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, Alcorcón, 28922 Madrid, SpainDepartment of Endocrinology and Nutrition, Hospital Universitario Infanta Leonor, 28031 Madrid, SpainDepartment of Endocrinology and Nutrition, Fundación Jiménez Díaz, 28040 Madrid, SpainDepartment of Endocrinology and Nutrition, Hospital Universitario de Móstoles, Móstoles, 28935 Madrid, SpainDepartment of Endocrinology and Nutrition, Hospital Universitario Puerta de Hierro, Majadahonda, 28222 Madrid, SpainDepartment of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, Alcorcón, 28922 Madrid, SpainThe aims of this multicentric retrospective study were to assess in a real-world setting the effectiveness and safety of canagliflozin 100 mg/d (CANA100) as an add-on to the background antihyperglycemic therapy, and to evaluate the intensification of prior sodium–glucose co-transporter type 2 inhibitor (SGLT-2i) therapy by switching to canagliflozin 300 mg/d (CANA300) in patients with T2DM. One cohort of SGLT2i-naïve patients with T2DM who were initiated on CANA100 and a second cohort of patients with prior background SGLT-2i therapy who switched to CANA300 were included in the study. The primary outcome of the study was the mean change in HbA1c over the follow-up time. In total, 583 patients were included—279 in the cohort of CANA100 (HbA1c 8.05%, weight 94.9 kg) and 304 in the cohort of CANA300 (HbA1c 7.51%, weight 92.0 kg). Median follow-up periods in both cohorts were 9.1 and 15.4 months respectively. CANA100 was associated to significant reductions in HbA1c (−0.90%) and weight (−4.1 kg) at the end of the follow-up. In those patients with baseline HbA1c > 8% (mean 9.25%), CANA100 lowered HbA1c levels by 1.51%. In the second cohort, patients switching to CANA300 experienced a significant decrease in HbA1c (−0.35%) and weight (−2.1 kg). In those patients with baseline HbA1c > 8% (mean 8.94%), CANA300 lowered HbA1c levels by 1.12%. There were significant improvements in blood pressure in both cohorts. No unexpected adverse events were reported. In summary, CANA100 (as an add-on therapy) and CANA300 (switching from prior SGLT-2i therapy) significantly improved several cardiometabolic parameters in patients with T2DM.https://www.mdpi.com/2077-0383/9/7/2275SGLT-2 inhibitorcanagliflozintype 2 diabetesswitch |
| spellingShingle | Juan J. Gorgojo-Martínez Manuel A. Gargallo-Fernández Alba Galdón Sanz-Pastor Teresa Antón-Bravo Miguel Brito-Sanfiel Jaime Wong-Cruz Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study Journal of Clinical Medicine SGLT-2 inhibitor canagliflozin type 2 diabetes switch |
| title | Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study |
| title_full | Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study |
| title_fullStr | Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study |
| title_full_unstemmed | Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study |
| title_short | Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study |
| title_sort | real world clinical outcomes associated with canagliflozin in patients with type 2 diabetes mellitus in spain the real wecan study |
| topic | SGLT-2 inhibitor canagliflozin type 2 diabetes switch |
| url | https://www.mdpi.com/2077-0383/9/7/2275 |
| work_keys_str_mv | AT juanjgorgojomartinez realworldclinicaloutcomesassociatedwithcanagliflozininpatientswithtype2diabetesmellitusinspaintherealwecanstudy AT manuelagargallofernandez realworldclinicaloutcomesassociatedwithcanagliflozininpatientswithtype2diabetesmellitusinspaintherealwecanstudy AT albagaldonsanzpastor realworldclinicaloutcomesassociatedwithcanagliflozininpatientswithtype2diabetesmellitusinspaintherealwecanstudy AT teresaantonbravo realworldclinicaloutcomesassociatedwithcanagliflozininpatientswithtype2diabetesmellitusinspaintherealwecanstudy AT miguelbritosanfiel realworldclinicaloutcomesassociatedwithcanagliflozininpatientswithtype2diabetesmellitusinspaintherealwecanstudy AT jaimewongcruz realworldclinicaloutcomesassociatedwithcanagliflozininpatientswithtype2diabetesmellitusinspaintherealwecanstudy |